HR4101Referred to Committee

Cancer Drug Parity Act of 2025

Share:
Introduced
In Committee
3
Passed One Chamber
4
Passed Both
5
Signed into Law
119th
Congress
2025-06-24
Introduced
29
Cosponsors
HR
ⓘ
Type

Sponsor

Glenn Grothman
Glenn Grothman
Republican · WI · Representative
Votes with party: 96.3% (640 recorded votes)

Full profile: /officials/G000576

Source: Congress.gov · FEC

Cosponsors (29)

Members who have signed on to support this bill since introduction. Source: Congress.gov.

Latest Action

The most recent step in the bill's legislative path. Committee Activity below shows referrals and reports; the full action-by-action history including floor proceedings lives at Congress.gov →

Referred to the House Committee on Education and Workforce.

2025-06-24

Source: Congress.gov

Committee Activity

Currently in

Plain-English Summary

This bill would require health insurance plans to treat cancer drugs the same way they treat other medications, preventing insurers from charging patients higher out-of-pocket costs or imposing stricter limits specifically for cancer treatments. The measure aims to make cancer drugs more affordable and accessible for patients by eliminating insurance practices that single out these medications for harsher coverage rules compared to drugs for other conditions.

AI-assisted summary generated from the official bill metadata (title, subjects, actions) sourced from Congress.gov. Cached and reviewed. Always verify against the official text linked below.

Subjects

Health
Full bill text is not yet cached locally.
Open text viewRead on Congress.gov

Related legislation

Bills by the same sponsor or covering overlapping subjects.